B-lymphocytes (or B-cells) occur much more frequently in metastasized prostate cancers than in small tumors and they also have an immunosuppressive effect. These cells suppress the immune system so that current treatments cannot work and malignant tumors are able to grow unchecked.
The international research group together with scientists from the University of California, the San Diego School of Medicine, the Charité Berlin, the Ludwig Boltzmann Institute for Cancer Research (LBI-CR), the Vetmeduni Vienna and the MedUni Vienna have now shown that, in combination with immunotherapy, a drug currently used in chemotherapy (oxaliplatin), can be effective even in otherwise therapy-resistant, advanced prostate cancers. This is achieved by blocking the activity and function of the B-cells beforehand.
"An added bonus is that this therapy is effective even with low-dose chemotherapy and is therefore much less stressful to the patient," explains one of the co-authors Lukas Kenner from the Vetmeduni Vienna. "It would also be reasonable to conclude that similar immunosuppressive B-cells are also present in other types of human cancer." This could therefore lead to new treatment options for other forms of cancer.
4,700 Austrians develop prostate cancer every year
Worldwide, prostate cancer is the third most frequent potentially terminal cancer in men and the sixth most frequent cause of death from cancer. According to Statistics Austria, around 4,700 men develop prostate cancer in Austria every year. Approximately 1,200 of those affected die during the same period. In the European Union, around 300,000 men are diagnosed with prostate cancer each year and there are around two million men living with this disease.
The article “Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy”, by Shabnam Shalapour, Joan Font-Burgada, Giuseppe Di Caro, Zhenyu Zhong, Elsa Sanchez-Lopez, Debanjan Dhar, Gerald Willimsky, Massimo Ammirante, Amy Strasner, Donna E. Hansel, Christina Jamieson, Christopher J. Kane, Tobias Klatte, Peter Birner, Lukas Kenner and Michael Karin will be published on the 29.4.2015 at 7:00 pm (CET). doi:10.1038/nature14395
About the University of Veterinary Medicine, Vienna
The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. www.vetmeduni.ac.at